SabyGeorgeMDFACP

Genitourinary Oncology, Hematologic Oncology

Professor of Oncology, Clinical/ Translational Investigator Director of Network Clinical Trials Roswell Park Cancer Institute

Join to view full profile

Dr. George is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. George's full profile

Already have an account?

Office
Elm And Carlton St
Buffalo, NY 14263
Phone+1 716-845-2300

Fax+1 716-845-3423

Summary

Dr. Saby George is an oncologist in Buffalo, NY and is affiliated with multiple hospitals in the area, including Cleveland Clinic, Miami Valley Hospital, and Roswell Park Comprehensive Cancer Center. He received his medical degree from Kottayam Medical College and has been in practice 18 years. He specializes in genitourinary oncology and hematologic oncology and is experienced in Urologic oncology with a particular research focus on Kidney cancer, prostate cancer, and bladder cancer.

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2010
Cleveland Clinic FoundationFellowship, Experimental Therapeutics In Medical Oncology, 2006 - 2008
Wright State UniversityResidency, Internal Medicine, 2003 - 2006
Kottayam Medical CollegeClass of 1999

Certifications & Licensure

NY State Medical License 2010 - 2025
OH State Medical License 2003 - 2025
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Clinical Trials

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer Start of enrollment: 2006 Oct 01
Terminated
Phase 1, Phase 2
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Oct 29
Active, not recruiting
Phase 1, Phase 2
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2010 Feb 06
Completed
Phase 1
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2012 Feb 01
Terminated
Phase 1
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate Start of enrollment: 2010 Mar 01
Terminated
Phase 1, Phase 2
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer Start of enrollment: 2012 Nov 21
Active, not recruiting
Phase 1, Phase 2
Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer Start of enrollment: 2013 Mar 14
Withdrawn
Not Applicable
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Start of enrollment: 2014 Jan 22
Active, not recruiting
Phase 3
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2015 Jan 01
Completed
Phase 2
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer Start of enrollment: 2015 Nov 11
Completed
Phase 2
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Start of enrollment: 2016 Jun 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

333 citations
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Laurence Albiges, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack
ESMO Open. 2020-11-01
156 citations
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Robert J Motzer, David F McDermott, Bernard Escudier, Mauricio Burotto, Toni K Choueiri
Cancer. 2022-06-01
2865 citations
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Nizar M. Tannir, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar
The New England Journal of Medicine. 2018-03-21

Press Mentions

Targeted Combination Shows Promise in Metastatic Kidney CancerNovember 13th, 2024
Roswell Park-Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney CancerSeptember 15th, 2024
Are Subcutaneous Drugs the Key to Cancer Care’s Future?August 20th, 2024
Join now to see all